Group 1 - The core point of the article is that Rundu Co., Ltd. has received a drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [2] Group 2 - The announcement was made on February 9, indicating a significant regulatory milestone for the company [2] - The approval of the drug may open new market opportunities for Rundu Co., Ltd. in the pharmaceutical sector [2] - This development highlights the company's ongoing efforts to expand its product portfolio and enhance its competitive position in the industry [2]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

Core Viewpoint - Rundu Co., Ltd. has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration, indicating the product's approval for the treatment of primary hypertension [1] Company Summary - Rundu Co., Ltd. is now authorized to market Candesartan Cilexetil Tablets, which are specifically indicated for primary hypertension [1]

Core Viewpoint - The company has received a drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration, indicating a significant regulatory approval for a new hypertension treatment [1] Group 1: Company Information - The drug is named Candesartan Cilexetil Tablets, with a dosage form of tablets and a specification of 16mg [1] - The registration classification of the drug is categorized as a Class 4 chemical drug [1] Group 2: Industry Relevance - The drug is indicated for the treatment of primary hypertension, which is a significant area in the pharmaceutical industry given the prevalence of hypertension globally [1]

Macro Highlights - The State Council issued an opinion to release the potential of sports consumption and promote high-quality development of the sports industry, proposing 6 key measures with 20 specific actions [1] - The measures include expanding the supply of sports products, stimulating consumer demand, strengthening sports enterprises, fostering growth points in the sports industry, enhancing support for industry elements, and improving service levels [1] - The National Standardization Administration plans to revise and formulate over 4,000 national standards focusing on key areas such as artificial intelligence and the Internet of Things to support the transformation and upgrading of the manufacturing industry [1] Company News - Jiahe Meikang announced that Hongyun Jiukang plans to reduce its stake in the company by no more than 1% [4] - Bolong Technology's supervisory board chairman intends to reduce his stake by no more than 0.75% [4] - Lianhuan Pharmaceutical received a drug registration certificate for Amlodipine Besylate Tablets [4] - Tianyu Co., Ltd. obtained a drug registration certificate for Candesartan Cilexetil Tablets [4] - Kebo Da plans to acquire 60% of Kebo Da Intelligent Technology for 345 million yuan [4] - Youyan Powder Materials reported that its newly developed heat dissipation copper powder cannot be used as a 3D printing material [4] - Southeast Network Frame won the bid for the joint development project of Wuyuan Street [4] - Lepu Medical completed the first dosing of the Phase II clinical trial for MWN105 injection [4] - Zhonghaidah clarified that its designated robot company is not UBTECH [4] - Information Development aims to expand cooperation opportunities with the Robotaxi industry chain [4] Additional Company News - Jingong Steel Structure's subsidiary won a land bid in Shanghai for 546 million yuan [5] - Fuyuan Pharmaceutical received a drug registration certificate for Amlodipine Benazepril Capsules [5] - Ningbo Construction's subsidiary won construction projects totaling 1.117 billion yuan [5]

Group 1 - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Norde Pharmaceutical Co., Ltd., has recently received the Drug Registration Certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [2]

Group 1 - The core point of the article is that Tianyu Co., Ltd. has received approval from the National Medical Products Administration for the drug registration certificate of Candesartan Cilexetil Tablets, which are indicated for primary hypertension [1] Group 2 - The approval was granted to Zhejiang Norde Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Tianyu Co., Ltd. [1] - Candesartan Cilexetil Tablets are specifically used for the treatment of primary hypertension [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd. (referred to as "Node Pharmaceutical"), has recently received the Drug Registration Certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration (NMPA) [1] Group 1 - Candesartan Cilexetil Tablets are indicated for the treatment of primary hypertension [1] - As of the announcement date, in addition to Node Pharmaceutical, there are 11 other domestic manufacturers producing this formulation, including Tian Di Heng Yi Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. [1]

Group 1 - The company Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration [1] - Candesartan Cilexetil Tablets are indicated for primary hypertension, with a total R&D investment of approximately 11.4476 million yuan by Node Pharmaceutical and its subsidiaries [1] - The projected sales revenue for Candesartan Cilexetil Tablets in domestic sample hospitals and urban retail pharmacies is approximately 294 million yuan in 2024 [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Node Pharmaceutical Co., Ltd., has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration, indicating the product's approval for the treatment of primary hypertension [1]. Company Summary - Tianyu Co., Ltd. has successfully obtained regulatory approval for Candesartan Cilexetil Tablets, which are indicated for primary hypertension [1]. - The approval enhances the product portfolio of Zhejiang Node Pharmaceutical Co., Ltd., potentially increasing its market presence in the hypertension treatment segment [1].